Cancer screenings still lagging after 82% drop during COVID-19 peak

Researchers expect to see an uptick in cancer mortality rates due to the drastic drop in screenings during the height of COVID-19, according to a study set to be presented next week at RSNA's annual meeting.

Cancer screening rates dropped by an astounding 82% from March-May 2020. Due to stay-at-home orders and the emphasis on social distancing, this was to be expected, experts noted. But it was assumed these numbers would recover once vaccination rates increased and imaging centers reopened fully. However, according to new research, this was not the case. 

“Once normal operations resumed, you’d expect that these patients were being imaged in an equitable way, but, in fact, it turns out that they weren’t,” explained senior author Marc Succi, MD, an emergency radiologist at Massachusetts General Hospital and executive director of the MESH Incubator. 

A new analysis suggests that cancer screenings and initial workups remain down 11.7% and 20%, respectively, from their pre-COVID numbers. Researchers suggest the reduction in CT cancer screenings could lead to more aggressive diagnoses for patients in the future, since routine screenings often spot problems before symptoms appear.

The team also highlighted an increase in cancer-related CTs across emergency departments during the study period. This implies that patients presented after symptoms kicked-in and were likely unaware of their illness, which further supports the theory providers will inevitably see more patients with advanced cancers, the authors explained.

Cancer patients remain in a precarious situation during the COVID era, the group added. While many are immunocompromised and especially vulnerable, missing cancer screenings, treatments and follow-ups could be detrimental for their long-term prognoses. 

“If a patient is due for a yearly lung cancer screening with a CT scan, we need to make sure they’re aware that they can and should get that screening regardless of COVID,” Succi added. “Delays in screening are inevitably going to lead to delayed diagnoses and increased morbidity.”

Look for full study details to be presented next week.

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.